Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma
Authors
Keywords
-
Journal
BLOOD
Volume 123, Issue 20, Pages 3128-3138
Publisher
American Society of Hematology
Online
2014-02-26
DOI
10.1182/blood-2013-10-535088
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Zoom Zoom: Racing CARs for Multiple Myeloma
- (2013) M. V. Maus et al. CLINICAL CANCER RESEARCH
- B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma
- (2013) R. O. Carpenter et al. CLINICAL CANCER RESEARCH
- CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications
- (2013) Y-T Tai et al. LEUKEMIA
- Evaluation of TNF superfamily molecules in multiple myeloma patients: Correlation with biological and clinical features
- (2013) Dorota Lemancewicz et al. LEUKEMIA RESEARCH
- Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma
- (2012) L. Santo et al. BLOOD
- Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival
- (2012) Eric Sanchez et al. BRITISH JOURNAL OF HAEMATOLOGY
- Phase I Trial of Anti-CS1 Monoclonal Antibody Elotuzumab in Combination With Bortezomib in the Treatment of Relapsed/Refractory Multiple Myeloma
- (2012) Andrzej J. Jakubowiak et al. JOURNAL OF CLINICAL ONCOLOGY
- Elotuzumab in Combination With Lenalidomide and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma
- (2012) Sagar Lonial et al. JOURNAL OF CLINICAL ONCOLOGY
- Despite quintuple disappointments, Lilly still charms investors
- (2012) Kathleen Raven NATURE MEDICINE
- 'Big data' deal for diabetes clinical trial modelling
- (2012) Charlotte Harrison NATURE REVIEWS DRUG DISCOVERY
- Structural basis for improved efficacy of therapeutic antibodies on defucosylation of their Fc glycans
- (2011) Tsunehiro Mizushima et al. GENES TO CELLS
- APRIL promotes cell-cycle progression in primary multiple myeloma cells: influence of D-type cyclin group and translocation status
- (2010) J. Quinn et al. BLOOD
- Antibody–drug conjugates: targeted drug delivery for cancer
- (2010) Stephen C Alley et al. CURRENT OPINION IN CHEMICAL BIOLOGY
- Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors
- (2010) M. de Weers et al. JOURNAL OF IMMUNOLOGY
- Antibody-maytansinoid conjugates for the treatment of myeloma
- (2010) Robert J. Lutz et al. mAbs
- Two mechanisms of the enhanced antibody-dependent cellular cytotoxicity (ADCC) efficacy of non-fucosylated therapeutic antibodies in human blood
- (2009) Shigeru Iida et al. BMC CANCER
- Functional Interaction of Plasmacytoid Dendritic Cells with Multiple Myeloma Cells: A Therapeutic Target
- (2009) Dharminder Chauhan et al. CANCER CELL
- The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Selective Cytotoxicity Against CD138-Positive Multiple Myeloma Cells In vitro and In vivo
- (2009) H. Ikeda et al. CLINICAL CANCER RESEARCH
- Milatuzumab – a promising new immunotherapeutic agent
- (2009) Zuzana Berkova et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- The Pharmacologic Basis for Antibody-Auristatin Conjugate Activity
- (2009) S. C. Alley et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Contribution of Linker Stability to the Activities of Anticancer Immunoconjugates
- (2008) Stephen C. Alley et al. BIOCONJUGATE CHEMISTRY
- APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells
- (2008) E. Belnoue et al. BLOOD
- Potent Anticarcinoma Activity of the Humanized Anti-CD70 Antibody h1F6 Conjugated to the Tubulin Inhibitor Auristatin via an Uncleavable Linker
- (2008) E. Oflazoglu et al. CLINICAL CANCER RESEARCH
- CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma
- (2008) E. D. Hsi et al. CLINICAL CANCER RESEARCH
- Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index
- (2008) C. F. McDonagh et al. MOLECULAR CANCER THERAPEUTICS
- IRF4 addiction in multiple myeloma
- (2008) Arthur L. Shaffer et al. NATURE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started